中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 7
Jul.  2017
Turn off MathJax
Article Contents

Advances in the application of GPC3 in treatment of liver cancer

DOI: 10.3969/j.issn.1001-5256.2017.07.037
Research funding:

 

  • Published Date: 2017-07-20
  • Liver cancer is one of the most common malignant tumors in the world, and traditional liver cancer treatment methods have their own limitations.Glypican-3 (GPC3) is a cell-surface heparan sulfate proteoglycan and is involved in the regulation of individual development and cell proliferation and differentiation.It is also a hepatoma-specific carcinoembryonic antigen.The mechanism of action of GPC3 in the development and progression of liver cancer has become a hot research topic.GPC3 not only has a unique value in the diagnosis of liver cancer, but also plays an important role in the treatment of liver cancer.This article also introduces the application of GPC3-derived tumor vaccines, GPC3 antibodies, GPC3 gene therapy, and targeted therapy and brings new ideas for the treatment of liver cancer.

     

  • loading
  • [1]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.
    [2]XU F, TANG B, DAI CL, et al.Research advances in risk factors for surgical site infection after liver cancer resection[J].Clin J Med Offic, 2016, 44 (8) :872-874. (in Chinese) 徐锋, 唐斌, 戴朝六, 等.肝癌切除术后手术部位感染危险因素研究新进展[J].临床军医杂志, 2016, 44 (8) :872-874.
    [3]PILIA G, HUGHES-BENZIE RM, MACKENZIE A, et al.Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome[J].Na Genet, 1996, 12 (3) :241-247.
    [4]HUYNH H, NGO VC, KOONG HN, et al.AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC) [J].J Hepatol, 2010, 52 (1) :79-87.
    [5]HUANG H, LIN J, RUAN J, et al.MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3[J].FEBS Lett, 2012, 586 (6) :884-891.
    [6]YU DD, DONG ZZ, YAO M, et al.Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA[J].Tumor Biol, 2013, 34 (2) :661-668.
    [7]CHEN J, YAO M, YAO DF, et al.Role of glypican-3 signaling pathways and therapeutic potential in hepatocellular carcinoma[J].J Clin Hepatol, 2013, 29 (1) :77-80. (in Chinese) 陈洁, 姚敏, 姚登福, 等.磷脂酰肌醇蛋白多糖-3介导的信号通路与肝癌靶向治疗[J].临床肝胆病杂志, 2013, 29 (1) :77-80.
    [8]YANG J, YAO M, WANG L, et al.Synergistic effect of intervention of glypican-3 gene transcription combined with antitumor drugs in inhibiting hepatoma cell proliferation[J].J Clin Hepatol, 2016, 32 (12) :2347-2352. (in Chinese) 杨婕, 姚敏, 王理, 等.干预磷脂酰肌醇蛋白多糖3基因转录联合抗肿瘤药物抑制肝癌细胞增殖的协同作用[J].临床肝胆病杂志, 2016, 32 (12) :2347-2352.
    [9]YAO M, WANG L, DONG Z, et al.Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy[J].Tumour Biol, 2014, 35 (6) :5857-5868.
    [10]WU YL, WANG YL, MU H, et al.Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine induced killer cells against hepatocellular carcinoma cells[J].Mol Med Rep, 2015, 11 (5) :3361-3367.
    [11]PAN Z, CHEN C, LONG H, et al.Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis[J].Mol Med Rep, 2013, 7 (3) :969-974.
    [12]SAWADA Y, YOSHIKAWA T, NOBUOKA D, et al.Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma:immunologic evidence and potential for improving overall survival[J].Clin Cancer Res, 2012, 18 (13) :3686-3696.
    [13]SAWADA Y, YOSHIKAWA T, FUJII S, et al.Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination[J].Hum Vaccin Immunotherapeutics, 2013, 9 (6) :1228-1233.
    [14]TADA Y, YOSHIKAWA T, SHIMOMURA M, et al.Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide[J].Int J Oncol, 2013, 43 (4) :1019-1026.
    [15]NOBUOKA D, MOTOMURA Y, SHIRAKAWA H, et al.Radiofrequency ablation for hepatocellular carcinoma induces glypican-3peptide-specific cytotoxic T lymphocytes[J].Int J Oncol, 2012, 40 (1) :63-70.
    [16]YORITA K, TAKAHASHI N, TAKAI H, et al.Prognostic significance of circumferential cell surface immunoreactivity of glypican-3in hepatocellular carcinoma[J].Liver Int, 2011, 31 (1) :120-131.
    [17]ISHIGURO T, SUGIMOTO M, KINOSHITA Y, et al.Anti-glypican 3 antibody as potential agent for huaman liver cancer[J].Cancer Res, 2008, 68 (23) :9832-9838.
    [18]ANDREW X, PHILIP J, ANTHONY B, et al.First-in-man phase Istudy of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res, 2013, 19 (4) :920-928.
    [19]IKEDA M, OHKAWA S, OKUSAKA T, et al.Japanese phase Istudy of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma[J].Cancer Sci, 2014, 10 (4) :345-348.
    [20]FENG MQ, GAO W, WANG RQ, et al.Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma[J].Proc Natl Acad Sci U S A, 2013, 110 (12) :1083-1091.
    [21]GAO W, TANG ZW, ZHANG YF, et al.Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis[J].Nat Commun, 2015, 6:6536.
    [22]HANAOKA H, NAGAYA T, SATO K, et al.Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy[J].Mol Pharm, 2015, 12 (6) :2151-2157.
    [23]GAO W, KIM H, HO M.Human monoclonal antibody targeting the heparan sulfate chains of Glypican-3 inhibits HGF-mediated migration and motility of hepatocellular carcinoma cells[J].PLo SOne, 2015, 10 (9) :7664-7669.
    [24]GAO W, KIM H, FENG M, et al.Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy[J].Hepatology, 2014, 60 (2) :576-587.
    [25]FENG M, HO M.Glypican-3 antibodies:a new therapeutic target for liver cancer[J].FEBS Letters, 2014, 588 (2) :377-382.
    [26]HANAOKA H, NAKAJIMA T, SATO K, et al.Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel[J].Nanomedicine (Lond) , 2015, 10 (7) :1139-1147.
    [27]MIAO HL, LEI CJ, QIU ZD, et al.MicroRNA-520c-3p inhibits hepatocellular carcinoma cell proliferation and invasion through induction of cell apoptosis by targeting glypican-3[J].Hepatol Res, 2014, 4 (3) :338-348.
    [28]XU MZ, YAO TJ, LEE NP, et al.Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma[J].Cancer, 2009, 115 (19) :4576-4585.
    [29]MIAO H, LEI CJ, WEN JY, et al.Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through downregulation of YAP[J].J Cell Biochem, 2013, 114 (3) :625-631.
    [30]MAGISTRI P, LEONARD SY, TANG CM, et al.The glypican 3hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling[J].J Surg Res, 2014, 18 (2) :377-385.
    [31]YANG XX, MA H.Research advances in tumor markers of hepatocellular carcinoma[J].J Clin Hepatol, 2016, 32 (4) :811-855. (in Chinese) 杨霄霄, 马红.肝细胞癌肿瘤标志物的研究进展[J].临床肝胆病杂志, 2016, 32 (4) :811-855.
    [32]YAO M, YANG Y, YAO DF, et al.Clinical value of circulating peripheral blood mononuclear cell glypican-3 mRNA and alpha fetoprotein for diagnosing and monitoring metastasis of hepatocellular carcinoma[J].J Clin Hepatol, 2012, 28 (10) :777-781. (in Chinese) 姚敏, 杨燕, 姚登福, 等.循环血单核细胞GPC3 mRNA和甲胎蛋白对肝癌诊断与转移监测的潜在价值[J].临床肝胆病杂志, 2012, 28 (10) :777-781.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1862) PDF downloads(450) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return